Psoriasis health indicator report
September 23, 2024
Gondo GC, Eakin G, Van Voorhees A, et al. Psoriasis health indicator report. National Psoriasis Foundation. Published January 2024.
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
June 30, 2024
Korman NJ, Warren RB, Bagel J, et al. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. J Dermatolog Treat. 2024;35(1):2371045.
Association between cardio‐cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population‐based data: A nested case–control study
July 30, 2023
Kim BR, Lee KH, Kim J, et al. Association between cardio-cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population-based data: A nested case-control study [published online ahead of print, 2023 Jul 30]. J Dermatol. 2023;10.1111/1346-8138.16904. doi:10.1111/1346-8138.16904
Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention
August 9, 2023
Eder L, Lee KA, Chandran V, et al. Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention [published online ahead of print, 2023 Aug 9]. Arthritis Rheumatol. 2023;10.1002/art.42661. doi:10.1002/art.42661
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
July 31, 2023
Armstrong AW, Park SH, Patel V, et al. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis [published online ahead of print, 2023 Jul 31]. Dermatol Ther (Heidelb). 2023;10.1007/s13555-023-00977-1. doi:10.1007/s13555-023-00977-1
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
June 29, 2023
Nikolopoulos D, Parodis I. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front Med (Lausanne). 2023;10:1217147. Published 2023 Jun 29. doi:10.3389/fmed.2023.1217147
View of Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians
March 28, 2023
Berna-Rico E, Abbad-Jaime de Aragon C, Garcia-Aparicio A, et al. Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians. Acta Derm Venereol. 2023;103:adv5087. Published 2023 Mar 28. doi:10.2340/actadv.v103.5087
AAD 2023 Highlights in Psoriatic Disease—Y-GRAPPiAns Newsletter March 2023
March 28, 2023
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study - ScienceDirect
March 6, 2023
Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatology. 2023;5(4):e200-e207. Pub date: March 6, 2023
Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
February 9, 2023
Eder L, Mathew AJ, Carron P, et al. Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(2):258-264. doi:10.3899/jrheum.220312
A phase II, randomized, double-blind, placebo-controlled trial in SLE
February 1, 2023
Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023;75(2):242-252. doi:10.1002/art.42391
Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study | Cardiology | JAMA Dermatology | JAMA Network
January 25, 2023
Zhao SS, Yiu ZZN, Barton A, Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study [published online ahead of print, 2023 Jan 25]. JAMA Dermatol. 2023;e226051. doi:10.1001/jamadermatol.2022.6051
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial
September 14, 2022
BMS Wins Landmark Approval in Plaque Psoriasis, Avoids Black Box Label
September 12, 2022
Prospective Cohort Study of Psoriatic Arthritis Risk in Patients With Psoriasis in a Real-World Psoriasis Registry
August 17, 2022
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
August 3, 2022
Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial [published online ahead of print, 2022 Aug 3]. Ann Rheum Dis. 2022;annrheumdis-2022-222405. doi:10.1136/ard-2022-222405
Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
July 15, 2022
Gossec L, Walsh JA, Michaud K, et al. Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey [published online ahead of print, 2022 Jul 15]. J Rheumatol. 2022;jrheum.211288. doi:10.3899/jrheum.211288
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
June 1, 2022
Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797-806. doi:10.1111/jdv.18044
FDA Approves First Systemic Treatment for Alopecia Areata
June 13, 2022
Pivotal trials: Two Phase 3 Trials of Baricitinib for Alopecia Areata - PubMed (nih.gov)
June 13, 2022
Adverse effects of anti-interleukin-23 agents employed in patients with psoriasis: a systematic review
June 13, 2022
Naik PP. Dermatology. 2022:1-11. Published online June 13, 2022]. doi:10.1159/000524199
Comorbidity in adult psoriasis: considerations for the clinician.
June 10, 2022
Daugaard C, Iversen L, Hjuler KF. Psoriasis (Auckl). 2022;12:139-150. doi:10.2147/PTT.S328572
Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
June 1, 2022
Morand E, Pike M, Merrill JT, et al. 2022 Copenhagen, Denmark, and Virtual EULAR Annual Congress. Ann Rheum Dis. 2022;81(Suppl 1):209. Abstract LB0004
Safety and efficacy of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis: 52-week results from a randomised phase 2 trial
June 1, 2022
Mease PJ, Deodhar A, Van der Heijde D, et al. 2022 Copenhagen, Denmark, and Virtual EULAR Annual Congress. Ann Rheum Dis. 2022;81(Suppl 1):842. Poster 1048.
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials.
March 1, 2022
Warren R, Armstrong A, Gooderham M, et al. SKIN J Cutan Med. 2022;6(2), s4. doi.org/10.25251/skin.6.supp.4
Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial.
February 1, 2022
Thaҫi D, Strober B, Gordon KB, et al. Dermatol Ther (Heidelb). 2022;12(2):495-510. doi:10.1007/s13555-021-00649-y
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
January 1, 2022
Krueger JG, McInnes IB, Blauvelt A. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869
